Skip to content

To explore the mechanism of Ming Mu Zhi Yang Steam and Wash Formula for treating type IV immunologic conjunctivitis by inhibiting macrophage activation via the NLRP3 inflammasome based on the "Qu Feng Zhi Yang" theory

To explore the mechanism of Ming Mu Zhi Yang Steam and Wash Formula for treating type IV immunologic conjunctivitis by inhibiting macrophage activation via the NLRP3 inflammasome based on the "Qu Feng Zhi Yang" theory

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300071793
Enrollment
Unknown
Registered
2023-05-25
Start date
2023-07-01
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

immunologic conjunctivitis

Interventions

1:A treatment group of 100 people (200 eyes, treated with Ming Mu Zhi Yang Steam and Wash Formula, 3 times per day). The Ming Mu Zhi Yang Steam and Wash Formula is a combination of traditional Chinese
2:100 outpatients (200 eyes) in the corticosteroid drug group given 0.1% flumiolone eye drops to them, trade name flumiphene, ginseng pharmaceutical, 3 times daily, lasts for 14 days.
3:100 outpatients (200 eyes) in the non-steroidal anti-inflammatory drug group , treated with diclofenac sodium eye drops, trade name Difei, Xingqi Pharmaceutical, 3 times daily, lasts for 14 days.
4:100 outpatients (200 eyes) in the antihistamine group, treated with eye drops of emestine fumarate, trade name: emetine, Alcon, 3 times daily, lasts for 14 days

Sponsors

The Second Affilated Hospital of Heilongjiang University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Diagnostic criteria for immunologic conjunctivitis The criteria for the diagnosis of immunologic conjunctivitis given by the consensus of experts in the clinical diagnosis and treatment of immunologic conjunctivitis and the eighth edition of "ophthalmology" were used 1. Eye itching or foreign body sensation with increased palpebral conjunctival papillae, blebs; 2. Eye itching or foreign body sensation with conjunctival hyperemia; 3. Itchy or foreign body sensation with bulbar conjunctiva or eyelid edema; 4. Eye itching or foreign body sensation with increased conjunctival sac secretions or Meibomian gland oifice secretions; 5. Itchy or foreign body sensation with corneal specific changes. A diagnosis of immune conjunctivitis was made when any of the above 5 items were met Patients with immune conjunctivitis inclusion criteria Those who met the diagnostic criteria for immunologic conjunctivitis without the following 1. There were no cases of keratitis, scleritis, pterygium, uveitis, endophthalmitis, corneal degeneration, and corneal ulcers; 2. No history of ocular surgery, trauma within 6 months, no history of ocular medication within 4 weeks, no hormone replacement therapy; 3. No corneal contact lens match history; 4. There were no structural abnormalities of the ocular surface or keratopathy; 5. No systemic disease.

Exclusion criteria

Exclusion criteria: Exclusion criteria for patients with immunologic conjunctivitis Not meeting immunologic conjunctivitis diagnosis with inclusion criteria or containing any of the following 1. Patients with ocular diseases such as glaucoma or cataract that require urgent treatment; 2. Patients had keratoconus or those with eye diseases other than immunologic conjunctivitis; 3. Pregnant women, infants, or poor compliance and inability to cooperate with examiners; 4. Withdrawal from study for personal reasons or failure to cooperate with investigator throughout.

Design outcomes

Primary

MeasureTime frame
Discharges in conjunctival sac;tear;

Secondary

MeasureTime frame
Palpebral conjunctival papilla;

Countries

China

Contacts

Public ContactRuoxi Liu

The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine

lanqingbingyu@163.com+86 189 4613 4100

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026